表征SARS-CoV-2抗体反应及其与患者因素的关联:GENCOV研究参与者的血清学分析

IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Clinical biochemistry Pub Date : 2025-01-01 DOI:10.1016/j.clinbiochem.2024.110859
Gregory Morgan , Chun Yiu Jordan Fung , Anne-Claude Gingras , Karen Colwill , Laurent Briollais , Erika Frangione , Dawit Wolday , Freda Qi , Adrian Pasculescu , Melanie Delgado-Brand , Genevieve Mailhot , Tulunay Tursun , Saranya Arnoldo , Erin Bearss , Alexandra Binnie , Bjug Borgundvaag , Selina Casalino , Sunakshi Chowdhary , Marc Dagher , Luke Devine , Jennifer Taher
{"title":"表征SARS-CoV-2抗体反应及其与患者因素的关联:GENCOV研究参与者的血清学分析","authors":"Gregory Morgan ,&nbsp;Chun Yiu Jordan Fung ,&nbsp;Anne-Claude Gingras ,&nbsp;Karen Colwill ,&nbsp;Laurent Briollais ,&nbsp;Erika Frangione ,&nbsp;Dawit Wolday ,&nbsp;Freda Qi ,&nbsp;Adrian Pasculescu ,&nbsp;Melanie Delgado-Brand ,&nbsp;Genevieve Mailhot ,&nbsp;Tulunay Tursun ,&nbsp;Saranya Arnoldo ,&nbsp;Erin Bearss ,&nbsp;Alexandra Binnie ,&nbsp;Bjug Borgundvaag ,&nbsp;Selina Casalino ,&nbsp;Sunakshi Chowdhary ,&nbsp;Marc Dagher ,&nbsp;Luke Devine ,&nbsp;Jennifer Taher","doi":"10.1016/j.clinbiochem.2024.110859","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The GENCOV study sought to evaluate serological differences between individuals with differing COVID-19 severity and outcomes. We assessed the SARS-CoV-2 antibody response of GENCOV participants cross-sectionally 1-, 6-, and 12-months following COVID-19 diagnosis to identify patient factors associated with more robust and durable humoral immune responses.</div></div><div><h3>Materials and Methods</h3><div>COVID-19 patients and a control cohort of vaccinated infection-naïve participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada. Commercially available and laboratory-developed serological assays were used to characterize features of participants’ antibody responses, including both binding and neutralizing antibodies. Regression analyses were performed to identify associations between participant characteristics and features of the SARS-CoV-2 antibody response.</div></div><div><h3>Results</h3><div>Samples were obtained from participants 1- (n = 938), 6- (n = 842), and 12-months (n = 662) post-infection or vaccination. At all time points, vaccinees, and to a greater extent those who were both infected and vaccinated, had significantly elevated anti-spike antibody levels compared to unvaccinated participants. Increasing age and/or illness severity were associated with significantly higher antibody levels among unvaccinated participants. Among vaccines, those who were vaccinated after infection (i.e., hybrid immunity) had consistently higher antibody levels compared to participants who were infection-naïve or vaccinated before their infection (i.e., breakthrough infections). Additionally, receiving more vaccine doses and having a more recent vaccination were strongly associated with higher antibody levels across all time points.</div></div><div><h3>Conclusions</h3><div>Our findings highlight various patient factors, including vaccination, which contribute to robust, durable SARS-CoV-2 antibody responses. Overall, the findings presented here may inform future vaccine development and rollout plans.</div></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":"135 ","pages":"Article 110859"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study\",\"authors\":\"Gregory Morgan ,&nbsp;Chun Yiu Jordan Fung ,&nbsp;Anne-Claude Gingras ,&nbsp;Karen Colwill ,&nbsp;Laurent Briollais ,&nbsp;Erika Frangione ,&nbsp;Dawit Wolday ,&nbsp;Freda Qi ,&nbsp;Adrian Pasculescu ,&nbsp;Melanie Delgado-Brand ,&nbsp;Genevieve Mailhot ,&nbsp;Tulunay Tursun ,&nbsp;Saranya Arnoldo ,&nbsp;Erin Bearss ,&nbsp;Alexandra Binnie ,&nbsp;Bjug Borgundvaag ,&nbsp;Selina Casalino ,&nbsp;Sunakshi Chowdhary ,&nbsp;Marc Dagher ,&nbsp;Luke Devine ,&nbsp;Jennifer Taher\",\"doi\":\"10.1016/j.clinbiochem.2024.110859\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>The GENCOV study sought to evaluate serological differences between individuals with differing COVID-19 severity and outcomes. We assessed the SARS-CoV-2 antibody response of GENCOV participants cross-sectionally 1-, 6-, and 12-months following COVID-19 diagnosis to identify patient factors associated with more robust and durable humoral immune responses.</div></div><div><h3>Materials and Methods</h3><div>COVID-19 patients and a control cohort of vaccinated infection-naïve participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada. Commercially available and laboratory-developed serological assays were used to characterize features of participants’ antibody responses, including both binding and neutralizing antibodies. Regression analyses were performed to identify associations between participant characteristics and features of the SARS-CoV-2 antibody response.</div></div><div><h3>Results</h3><div>Samples were obtained from participants 1- (n = 938), 6- (n = 842), and 12-months (n = 662) post-infection or vaccination. At all time points, vaccinees, and to a greater extent those who were both infected and vaccinated, had significantly elevated anti-spike antibody levels compared to unvaccinated participants. Increasing age and/or illness severity were associated with significantly higher antibody levels among unvaccinated participants. Among vaccines, those who were vaccinated after infection (i.e., hybrid immunity) had consistently higher antibody levels compared to participants who were infection-naïve or vaccinated before their infection (i.e., breakthrough infections). Additionally, receiving more vaccine doses and having a more recent vaccination were strongly associated with higher antibody levels across all time points.</div></div><div><h3>Conclusions</h3><div>Our findings highlight various patient factors, including vaccination, which contribute to robust, durable SARS-CoV-2 antibody responses. Overall, the findings presented here may inform future vaccine development and rollout plans.</div></div>\",\"PeriodicalId\":10172,\"journal\":{\"name\":\"Clinical biochemistry\",\"volume\":\"135 \",\"pages\":\"Article 110859\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical biochemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S000991202400153X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S000991202400153X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

GENCOV研究旨在评估不同COVID-19严重程度和结局的个体之间的血清学差异。我们评估了GENCOV参与者在COVID-19诊断后1、6和12个月的SARS-CoV-2抗体反应,以确定与更强大和持久的体液免疫反应相关的患者因素。材料和方法:在加拿大安大略省大多伦多地区的医院招募了COVID-19患者和接种疫苗infection-naïve的对照队列参与者。市售和实验室开发的血清学分析用于表征参与者抗体反应的特征,包括结合抗体和中和抗体。进行回归分析以确定参与者特征与SARS-CoV-2抗体反应特征之间的关联。结果:从感染或接种疫苗后1- (n = 938)、6- (n = 842)和12个月(n = 662)的参与者中获得样本。在所有时间点,与未接种疫苗的参与者相比,接种疫苗者,以及在更大程度上既感染又接种疫苗的人,抗刺突抗体水平显著升高。在未接种疫苗的参与者中,年龄和/或疾病严重程度的增加与抗体水平的显著升高相关。在疫苗接种中,感染后接种疫苗的人(即混合免疫)的抗体水平始终高于感染前接种infection-naïve或接种疫苗的参与者(即突破性感染)。此外,在所有时间点上,接受更多的疫苗剂量和最近的疫苗接种与更高的抗体水平密切相关。结论:我们的研究结果强调了包括疫苗接种在内的各种患者因素,这些因素有助于产生稳健、持久的SARS-CoV-2抗体反应。总的来说,这里提出的研究结果可能为未来的疫苗开发和推广计划提供信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study

Introduction

The GENCOV study sought to evaluate serological differences between individuals with differing COVID-19 severity and outcomes. We assessed the SARS-CoV-2 antibody response of GENCOV participants cross-sectionally 1-, 6-, and 12-months following COVID-19 diagnosis to identify patient factors associated with more robust and durable humoral immune responses.

Materials and Methods

COVID-19 patients and a control cohort of vaccinated infection-naïve participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada. Commercially available and laboratory-developed serological assays were used to characterize features of participants’ antibody responses, including both binding and neutralizing antibodies. Regression analyses were performed to identify associations between participant characteristics and features of the SARS-CoV-2 antibody response.

Results

Samples were obtained from participants 1- (n = 938), 6- (n = 842), and 12-months (n = 662) post-infection or vaccination. At all time points, vaccinees, and to a greater extent those who were both infected and vaccinated, had significantly elevated anti-spike antibody levels compared to unvaccinated participants. Increasing age and/or illness severity were associated with significantly higher antibody levels among unvaccinated participants. Among vaccines, those who were vaccinated after infection (i.e., hybrid immunity) had consistently higher antibody levels compared to participants who were infection-naïve or vaccinated before their infection (i.e., breakthrough infections). Additionally, receiving more vaccine doses and having a more recent vaccination were strongly associated with higher antibody levels across all time points.

Conclusions

Our findings highlight various patient factors, including vaccination, which contribute to robust, durable SARS-CoV-2 antibody responses. Overall, the findings presented here may inform future vaccine development and rollout plans.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical biochemistry
Clinical biochemistry 医学-医学实验技术
CiteScore
5.10
自引率
0.00%
发文量
151
审稿时长
25 days
期刊介绍: Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.
期刊最新文献
Assessment of accuracy, clinical validity, and analytical linearity in point-of-care glucose monitoring devices for diabetes mellitus: A systematic review and meta-analysis Rising illicit drug Adulterants: Xylazine and levamisole. Phosphatidylethanol clearance after packed red blood cell transfusion Editorial Board Cardiac troponin I is associated with ICU admission in pediatric patients with RSV
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1